Perspective Therapeutics, Inc.
CATX
Rank in Stocks
#19778
Perspective Therapeutics, Inc., including its various operations, specializes... Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle β from development and manufacturing to sales and marketing β of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Share Price
$0.8556
Last synced: 2026-11-09
Market Cap
$97.67M
Change (1 day)
1.86%
Change (1 year)
-61.46%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Perspective Therapeutics, Inc. (CATX)
Category
Healthcare
Operating Margin for Perspective Therapeutics, Inc. (CATX)
Operating Margin as of November 2026 TTM: -34,216.39%
According to Perspective Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -34,216.39%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Perspective Therapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -34,216.39% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -2,855.02% | 1,235.93% |
| 2022 | -213.71% | 525.07% |
| 2021 | -34.19% | -4.79% |
| 2020 | -35.91% | -50.24% |
| 2019 | -72.16% | -36.48% |
| 2018 | -113.61% | -14.24% |
| 2017 | -132.47% | 24.31% |
| 2016 | -106.56% | 13.21% |
| 2015 | -94.13% | -13.44% |
| 2014 | -108.75% | 20.99% |
| 2013 | -89.88% | 26.68% |
| 2012 | -70.95% | 25.44% |
| 2011 | -56.56% | -25.42% |
| 2010 | -75.84% | -36.50% |
| 2009 | -119.43% | -2.88% |
| 2008 | -122.97% | -27.25% |
| 2007 | -169.04% | -53.15% |
| 2006 | -360.79% | -81.73% |
| 2005 | -1,974.51% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
| 2000 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.00% |
US
|
|
| 18.08% | -100.00% |
IE
|
|
| 21.25% | -100.00% |
US
|
|
| 21.05% | -100.00% |
US
|
|
| 28.09% | -100.00% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Perspective Therapeutics, Inc.'s operating margin
What is Perspective Therapeutics, Inc.'s operating margin?
Perspective Therapeutics, Inc.'s operating margin is -34,216.39%, as of Nov 2026.
What was Perspective Therapeutics, Inc.'s operating margin in 2025?
In 2025, Perspective Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Perspective Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Perspective Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2023 (-2,855.02%).
How does Perspective Therapeutics, Inc.'s operating margin compare with similar companies?
Perspective Therapeutics, Inc.'s operating margin (-34,216.39%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.